Home › Recurrent respiratory papillomatosis › NCT06412172
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: * History of HPV-associated Recurrent Respiratory Papillomatosis * Has pulmonary lesions Exclusion Criteria: * None
About the study
Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. The investigators hypothesize that by understanding the biology of RRP and the failed host immune responses against HPV, novel and rational therapies can be developed. This study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with RRP.
Sponsor: Massachusetts General Hospital · Participants: 100 · Started: Apr 15, 2024
Contact the study team
- Sara Pai, MD, PhD · Phone: 203-785-5820
Official record on ClinicalTrials.gov — NCT06412172
Locations in the U.S.
| Connecticut | Yale School of Medicine, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.